Sarcopenia to Be Addressed in an FDA PFDD Meeting

Sarcopenia has been chosen as one of eight conditions the U.S. Food and Drug Administration will hold patient-focused drug development (PFDD) meetings on in fiscal years 2016 and 2017. The FDA’s Center for Drug Evaluation and Research (CDER) chose sarcopenia after receiving more than 2,700 public comments related to 50 different diseases. Learn more here.